Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph not_applicable
1
20%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
unknown1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
66.7%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

completed240%
unknown120%
recruiting120%
terminated120%

Recent Activity

1 active trials
Showing 5 of 5
terminated

Predicting Cognitive Decline From Androgen Deprivation Therapy

NCT05820932
recruiting

QOL and Sarcopenia in Patients With Ascites

NCT05726747
completed

Survey Study: Financial Impact of Breast Cancer Treatment

NCT03615573
unknownnot_applicable

Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester

NCT05099237
completed

Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma

NCT03493737

Clinical Trials (5)

Showing 5 of 5 trials
NCT05820932

Predicting Cognitive Decline From Androgen Deprivation Therapy

Terminated
NCT05726747

QOL and Sarcopenia in Patients With Ascites

Recruiting
NCT03615573

Survey Study: Financial Impact of Breast Cancer Treatment

Completed
NCT05099237Not Applicable

Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester

Unknown
NCT03493737

Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma

Completed

All 5 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
5